Navigation Links
Clinical Data Reported on Vidaza in Hematologic Malignancies and,Advanced Solid Tumors

rstCall/ -- Exelixis, Inc. (Nasdaq: EXEL) reported data from the Phase I clinical trial program for XL880, a novel small molecule compound that simultaneously inhibits MET and VEGFR2, targets implicated in tumor growth, tumor cell migration, and angiogenesis. Patricia M. LoRusso, D.O., Director of the Phase I Clinical Trials Program at the Barbara Ann Karmanos Cancer Institute, Professor of Hematology and Oncology at Wayne State University, and a lead investigator in the trial, presented the data in the Developmental Therapeutics: Molecular Therapeutics oral abstract session (Abstract #3526) at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO).

The data presented were taken from two Phase I studies of XL880 in patients with advanced solid tumors. One study evaluated an intermittent, weight-based dosing regimen and the other evaluated fixed daily dosing. Both studies included pharmacokinetic, pharmacodynamic, and tumor response analyses.

Five partial responses (>30% tumor regression by RECIST) were observed, including three in papillary renal cell cancer, one in medullary thyroid cancer, and one in hurthle cell thyroid cancer. Tumor shrinkage of less than 30% or prolonged stable disease of greater than 3 months was observed in an additional 20 patients. Additionally, in a best response evaluation as determined by RECIST criteria, investigators reported that 39 of 45 patients in the combined phase 1 studies had either tumor regression or stable disease.

"We consider the number of patients with responses or disease stabilization in these studies to be quite striking, particularly in light of these patients' advanced disease," said Dr. LoRusso. "We believe XL880 has significant potential as a novel cancer therapy, and the ongoing Phase II trials should provide important insight into the late stage development plans for the compound."

Histological analyses of tumor samples from four patients showed decreases in the ph
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
4. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
Post Your Comments:
(Date:12/16/2009)... Medical Inc. today announced the treatment of the ... surgical adhesive product, TissuGlu®. Initiation of the study ... of the lead product toward clinical practice. ... randomized study to investigate the safety of TissuGlu ... complications in abdominoplasty, or "tummy tuck," surgeries. The ...
(Date:12/16/2009)... Dec. 16 CareCentrix, Inc ., ... management services, announced today that it has been ... DC-based health care accrediting organization that establishes quality ... guarantee that only appropriately trained, qualified clinical personnel ... a reasonable and timely appeals process is in ...
(Date:12/16/2009)... CHARLOTTESVILLE, Virginia, December 16 Biovista Inc.,today ... Innovator Presentation Award,in Healthcare, at the 2009 New ... MA. The award, which recognizes cutting edge private ... Biovista who competed with,over 50 other privately held ... the Technology, Life Sciences and Clean-tech sectors. , ...
Breaking Medicine Technology:First Patient Treated in Clinical Study of Cohera Medical's TissuGlu(R) Surgical Adhesive 2First Patient Treated in Clinical Study of Cohera Medical's TissuGlu(R) Surgical Adhesive 3CareCentrix Receives URAC Health Utilization Management Accreditation 2Biovista Inc. Named Top Innovator in Life Sciences 2Micell Receives 2415 Million Equity Investment 57861 1Senator Proposes Use of Internet Gambling Revenue to Help Fund Health Care Reform 57860 1Senator Proposes Use of Internet Gambling Revenue to Help Fund Health Care Reform 57860 2New Report Highlights Proven Disease Prevention Programs in Communities 57858 1New Report Highlights Proven Disease Prevention Programs in Communities 57858 2New Report Highlights Proven Disease Prevention Programs in Communities 57858 3New Report Highlights Proven Disease Prevention Programs in Communities 57858 4
... Foundation to Introduce a Nutritional Product to ... Loss, Protect against Hearing Impairment, NASHVILLE, Tenn., ... launch of a Hearing Health micronutrient,supplement designed to ... protection against hearing impairment and balance disorders.,Previously available ...
... Incorporated,(Nasdaq: VICL ) today announced that data ... its patented Vaxfectin(TM) adjuvant to be used as ... vaccine,currently stockpiled by the U.S. government. Dose-sparing ability ... protect the greatest,number of people in the event ...
Other Medicine Technology:Premier Micronutrient Launches Supplement for Hearing Health 2Premier Micronutrient Launches Supplement for Hearing Health 3Vical Demonstrates Dose-sparing of Protein-based H5N1 Influenza Vaccine With Vaxfectin(TM) Adjuvant 2Vical Demonstrates Dose-sparing of Protein-based H5N1 Influenza Vaccine With Vaxfectin(TM) Adjuvant 3Vical Demonstrates Dose-sparing of Protein-based H5N1 Influenza Vaccine With Vaxfectin(TM) Adjuvant 4
(Date:12/17/2009)... last few weeks there has been an increase of ... e cigarette opposition in an attempt to scare the ... tactics of these groups when the evidence clearly shows ... tobacco according to several studies, lab reports and opinions ... world. ,, Special interest groups appear to have ...
(Date:12/17/2009)... Calif., Dec. 17 Abaxis, Inc. (Nasdaq: ... point-of-care blood analysis instruments and rapid tests for ... that it has entered the production animal diagnostics ... Influenza Antigen Test. This is a USDA-licensed test ... chickens, turkeys and ducks. The disposable, non-instrumented device, ...
(Date:12/17/2009)... LONDON, December 17 Researchers from the ... Loughborough University in the UK are today,encouraging ... in the,New Year following concerning research* that shows ... together as a family (68%), with the,Portuguese being ... likely to,walk together. , ...
(Date:12/17/2009)... functions were determining factors. StaffKnex, developers of web-based nurse ... selected by Lifespace Communities to deliver its software solution ... ... Cleveland, OH (PRWEB) December 17, ... nurse scheduling and employee communication software, recently announced it ...
(Date:12/17/2009)... engines like Google Local and in front of their local customers ... Registration service offered by New Orleans based Webtyde Internet Marketing. ... ... In order to be competitive locally and nationally, businesses must have ... local map section in a major search engine, a business must ...
Breaking Medicine News(10 mins):Health News:Special Interest Deceptions Continue to Rampant About Electronic Cigarettes 2Health News:ABAXIS(R) Announces Exclusive Worldwide OEM Agreement for a Lateral Flow Avian Influenza Antigen Test Kit 2Health News:ABAXIS(R) Announces Exclusive Worldwide OEM Agreement for a Lateral Flow Avian Influenza Antigen Test Kit 3Health News:ABAXIS(R) Announces Exclusive Worldwide OEM Agreement for a Lateral Flow Avian Influenza Antigen Test Kit 4Health News:The Family Walk - a Dying Tradition Around the World? 2Health News:Lifespace Communities Selects StaffKnex Software for Nurse Scheduling and Employee Communications 2Health News:Lifespace Communities Selects StaffKnex Software for Nurse Scheduling and Employee Communications 3Health News:New Orleans Based Internet Marketing Is Helping Small Businesses Get a Chance to Shine On the Web 2
... that evening administration of the central alpha(2)-agonists guanabenz ... the morning in hypertensive patients. The study was ... receive once-daily evening administration of guanabenz or clonidine ... of the two drugs in the morning and ...
... lifestyle with limiting TV time could prevent obesity and type ... watching results in a lower metabolic rate when compared to ... a car. Prolonged TV watching is also linked to obesity ... and hardly concentrate on reducing sedentary behaviours.// ...
... that treatment with adult stem cells has cured mice ... have recovered completely from paralysis of their back legs, ... with stem cells extracted from the brains of adult ... showed that the stem cells had migrated to and ...
... in Journal of the American College of Cardiology suggests ... profile for the heart when delivered through a patch ... the largest study of its kind, was cut short ... Replacement Therapy (a combination of estrogen and progestin) increased ...
... glucose levels are above normal. People with diabetes have ... into a sugar called glucose, which is carried by ... the hormone insulin, made in the pancreas, to help ... can prevent or delay complications by keeping blood glucose ...
... discuss with their physicians, can be an early warning ... disease, hypertension, diabetes, high cholesterol, obesity and smoking are ... estimated that Erectile dysfunction affects 40 million men, yet ... tell and doctors never ask.// ED is one symptom ...
Other Medicine News:
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: